Emmanuelle J. Meuillet

There is great news for Illumina embedded in a new DeciBio liquid biopsy report. DeciBio projects the LB market to grow at 30% and reach $10B in 2029 and as they note, it's a crowded market with numerous approaches. But NGS is the common them as it's the ubiquitous technology for generating data for DNA, Methylation, RNA and multiomics (assuming genomics is base-line in omics). Trying to put a number on this effect from the figure below, NGS is the underlying technology for 151/217 = 70% of the LB companies. That makes LB a huge opportunity for Illumina (primarily) and other low cost SR providers. Situation is challenging for LR (PacBio and Oxford Nanopore Technologies) and slow/no scaling SR providers (Thermo Fisher Scientific, gotta buy Element Biosciences🤣).

165

14 Comments

Roche's recent decision to offload their Vacaville facility highlights the increasing importance of cell line productivity in biomanufacturing strategy. According to Dan Stanton of Bioprocess Insider, Roche is moving towards more high titer processes and products with lower volume demands. (You can read the article here https://lnkd.in/erRx597k) Agile manufacturing strategies are enabled by cell line productivity, which allows for the same amount of drug substance to be produced in smaller bioreactors. This, in turn, allows for smaller clean rooms and lower running costs. Just - Evotec Biologics' J.CHO High Expression System cell lines, grown in perfusion bioreactors, produce over 4 g/L of antibody each day, equivalent to around 30 g/L in fed-batch mode (https://lnkd.in/eexeJrQA). This level of productivity allows for commercial quantities of antibody to be manufactured in 1000L single-use bioreactors in our modular J.POD facilities. As a result, large-scale stainless-steel facilities are becoming redundant. The future of biomanufacturing lies in maximizing cell line productivity, and our J.CHO system is leading the way. #biomanufacturing #celllineproductivity #JCHO #JPod #agilemanufacturing 👨‍⚕️Philip Boehme

36

In vivo spatial single cell level screening for CGT drug development, Waypoint is the new kid on the block with 14.5M in their pocket...... They write: Waypoint’s platform – which uniquely combines spatial biology with pooled screening for the purpose of drug discovery – can conduct initial screens of cell therapy designs in vivo and simultaneously measure hundreds of phenotypes at the single cell level, helping illuminate which designs work and why

3

What if you could de-risk your lead candidate earlier in the project, using human proteins & primary human tissues? Discovery | Charles River have a streamlined and efficient multi-disciplinary approach given you highly valuable insights. Contact me to discuss how our process can help your project! #drugdiscovery #derisking Nick Brown Lisa Scandiuzzi, PhDGemma Moiset, Namrata Jayanth, Omar Aziz

4

DRAGEN V4.3…making huge strides with difficult genes. New specialized callers enable genotyping of genes such as PMS2, NEB, IKBKG etc. in segmental duplication regions

20

New gene amplification tool called amplification editing, may benefit the CGT field with its capability of up to Mb level duplication in ES and primary cell They write: AE achieves duplication of 20 bp to 100 Mb with high efficiency and precision • AE generates multiple repeats with duplication ranging from 20 bp to 8 kb • Mb-level duplications have been realized in embryonic stem cells and primary cells • AE treatment can upregulate expressions of non-coding RNA and a coding gene https://lnkd.in/ekD8jGfJ

2

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

Hey there, drug development pioneers! Could it be that #DDI studies ahead in your journey seem like too much too handle, yet unavoidable? I invite you to check below how our of-the-shelf #assay, developed by the expert team at Aliri Bioanalysis might save you the trouble😉! Enjoy🤓

11

In Q2 2024, the FDA approved several new drugs, as detailed in a recent analysis by Paul Verdin at Evaluate Pharma. Highlights include the first IL-15 receptor agonist, a telomerase inhibitor, and others. The following are some of the interesting ones. Anktiva (nogapendekin alfa inbakicept): Indication: BCG-unresponsive non-muscle invasive bladder cancer. Mechanism: Activates NK and CD8+ T cells, and CD4+ helper T cells. Sales Forecast: Over $1.6 billion by 2030. Approval: FDA breakthrough designation. Ohtuvayre (ensifentrine): Indication: Maintenance treatment of COPD. Mechanism: PDE3/4 inhibitor. Sales Forecast: $1.5 billion by 2030. Significance: First novel inhaled COPD therapy in over 20 years. Rytelo (imetelstat): Indication: Low- to intermediate-1 risk myelodysplastic syndromes. Mechanism: Inhibits telomerase, reducing malignant cell proliferation. Sales Forecast: $1.3 billion by 2030. Ojemda (tovorafenib): Indication: Relapsed/refractory pediatric low-grade glioma. Mechanism: Pan-RAF kinase inhibitor. Sales Forecast: Over $1 billion by 2030. Approval: Accelerated approval, requires confirmatory evidence. https://bit.ly/3S6i9Nw

19

Did you know that NeoGenomics Laboratories has a series of blogs that highlight some of our latest publications, notable research as well as conference summaries? Check out my latest blog from #aacr24, there was a lot to cover, so its split into two parts, the first of which covers some updates on novel drug targets. https://lnkd.in/eFYjuG4B #oncology, #ADC, #CAR, #PROTAC, #Bispecific, #immunotherapy,

62

Fascinating work! Transforming public antibody clones into therapeutics to save human lives!! Six years ago, I was inspired to write this correspondence in Nature (https://lnkd.in/dmY7t3k) when I noticed a convergence between some therapeutic antibodies and antibody sequences from published Next-Generation Sequencing (NGS) data. I realized there was a lack of proper sequence annotations and analysis pipelines for the NGS data deposited at the Sequence Read Archive (SRA) and considered the patent issues in the era of NGS. #mabs #mab #antibody #antibodies #biologics #vaccines #vaccine #therapeutics

19

The VisionSort Platform is Headed to CYTO, AAI and ARVO! Join us and learn about the next frontier in cytometry for Cell Therapy R&D, Drug Discovery, and Disease Profiling. Bringing together fundamental advances in optics, microfluidics, and artificial intelligence (AI), VisionSort empowers researchers to get more from their cells. VisionSort was designed to deliver all the capabilities you have come to expect from traditional fluorescence-only cytometers and adds the strength of morphological profiling and insights of AI. Go beyond conventional cytometry add a new dimension to your cellular analysis and sorting workflows with VisionSort. https://hubs.li/Q02vB10b0 #CYTO2024 #CYTO24 #ARVO2024 #ARVO24 #AAI2024 #AAI24 #flowcytometry #AI #labelfree

23

1 Comment

Did you know that Bio-Blocks are mass produced uniformly and consistently? Once your cells start creating, their 3D substrate will stay the same. Read more about it here: https://bit.ly/3KEQnDH #cellculture #biotechnology #scienceandtechnology #ronawk

14

Among the multitude of single-cell technologies, which one should you choose? A comprehensive benchmarking study by a team from Genentech can help make that choice easier. They used PBMCs to evaluate the performance of droplet, microwell, and combinatorial indexing-based methods from various companies that offer single-cell technology. 07/08/24 edit: please see response from Singleron by Harlin Jhyont below in the comment. “This study provides a comprehensive and systematic evaluation of commercially-available scRNA-seq kits and sheds light on the various strengths and weaknesses of each kit with respect to time, cost, functionality and performance, which should facilitate an optimal and informed selection of a suitable scRNA-seq approach.” “Overall, 10x FRP exhibited the highest ranked performance followed by 10x 3’, BD, Scale, 10x 5’ / Parse (tie), Fluent, Honeycomb, and Scipio. Singleron was excluded from the cell-based comparisons due to unreliable cell calling; however, based on UMI count, gene count, and usable mapped reads, it exhibited the lowest performance at the library level.” https://lnkd.in/eTk3jYVQ #singlecell #science

147

6 Comments

Thanks Fred Grier and the team from San Diego Business Journal for your write up today on Bright Peak Therapeutics. We appreciate your coverage and commitment to the local biotech business community! Click on the link below for full access to the article

65

Discover Anjarium Biosciences novel anion exchange ligand poster for purifying Lentivirus vectors (LVVs), featured at the ASGCT 2024 conference in Baltimore. When the ligand is attached to a resin matrix, it can either directly capture LVVs from clarified media or be utilized in a polishing step. Over 60% of infectious lentivirus can be reliably recovered under unprecedented physiological elution conditions (150 mM salt, pH 7 to 8), surpassing the performance of the industry-leading DEAE ligand. Find all our presented posters about Lentivirus vector purification and our synthetic DNA technology at https://www.anjarium.com/ #ASGCT2024 #lentivirus #chromatography #downstreamprocessing #genetherapy #celltherapy #CART #biotech

28

2 Comments

UC Irvine study reveals circadian clock can be leveraged to enhance cancer immunotherapy Optimizing individual time-of-day delivery offers new avenues for prevention and treatment Irvine, Calif., May 28, 2024 — A multidisciplinary research team at the University of California, Irvine has revealed that the circadian clock – the biological pacemaker that governs daily rhythms in physiological processes, including immune functions – can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy. Checkpoint inhibitors block different proteins from binding to tumor cells, allowing the immune system’s T cells to kill the tumor. The study, published online today in the journal Nature Immunology, provides deeper insights into the intricate relationship among the circadian clock, immune regulation and tumor development and found that a therapeutic approach optimizing time-of-day delivery based on an individual’s unique circadian patterns offers new avenues for prevention and treatment. “Disruption of the internal biological pacemaker is an inherent aspect of modern society that may contribute to the rising incidence of many cancer types. We found that proper regulation of circadian rhythms is necessary to suppress inflammation and support peak immune function,” said corresponding author Selma Masri, UC Irvine associate professor of biological chemistry. “Understanding precisely how circadian disruption promotes disease progression could lead to behavior modification to reduce cancer risk.” Team members used an advanced single-cell RNA sequencing technique in a genetic model of colorectal cancer and identified clock-dependent changes controlling the number of myeloid-derived cells that suppress T cell activation. They discovered that disruption of the internal clock in the epithelial cells lining the intestine alters secretion of cytokine proteins, leading to heightened inflammation, increased numbers of immunosuppressive myeloid cells and cancer progression. These findings were leveraged to demonstrate that providing immunotherapy at the time of day when these immunosuppressive myeloid cells are most abundant significantly enhanced the efficacy of immune checkpoint blockades in solid tumors. https://lnkd.in/eJFkhSVi https://lnkd.in/ena2V39T

14

New vinylsulfonyl piperazine handle for DCF16 E3 ligase targeting covalent degraders.

5